GENinCode (LON:GENI) Sets New 52-Week Low – Should You Sell?

GENinCode Plc (LON:GENI) reached a new 52-week low on Thursday. The stock traded as low as GBX 0.50 and last traded at GBX 0.58, with a volume of 2,533,418 shares. The stock had previously closed at GBX 0.55.

GENinCode Stock Up 3.4%

The business’s 50 day moving average price is GBX 0.77 and its 200-day moving average price is GBX 0.97. The company has a debt-to-equity ratio of 4.75, a current ratio of 2.22 and a quick ratio of 15.88. The company has a market cap of £4.52 million, a P/E ratio of -0.47 and a beta of 0.59.

GENinCode (LON:GENI) last announced its earnings results on Tuesday, September 29th. The company reported GBX (0.38) EPS for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. On average, analysts anticipate that GENinCode Plc will post -7.13 earnings per share for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.